Jiangsu Kingsley Pharmaceutical Co.,Ltd. is a state-owned medium-sized enterprise invested and founded jointly by Kingsley Group Company of Jiangsu Tobacco Company and Yunnan Hongta Group of Yunnan Tobacco Company. The company is a high-tech enterprise of Jiangsu Province as well as the first genetic engineering industrialization base of Jiangsu Province. On Dec 10, 1997, the company passed GMP Certification by State Ministry of Health and was granted GMP Certificate by State Medicine Accreditation Committee. It is the first bio-pharmaceutical company that has passed GMP Certification within China.
The company specializes in production of freeze-dried powder with annual production capacity of 20 million bottles. The major products are recombinant human interleukin-2, azithromycin for injection, omeprazole sodium for injection, pantoprazole sodium for injection, thymopentin for injection, pentoxifylline for injection, dextromethorphan hydrobromide for injection, diammonium glycyrrhizinate for injection, ganciclovir for injection, clindamycin phosphate for injection, etc. Recombinant Human Interleukin-2 for Injection ranks the first in domestic market share. Our company is the first domestic company who has successfully developed and launched Azithromycin for Injection and now it ranks among top ten in market share.
Since founded in 1992, the company has consistently abided by the management principle of “based on high quality and focusing on science & technology”, continuously strengthened enterprise management, focused on talent education, attached great importance to quality, made efforts to develop market and constructed good company image in the market. Both Recombinant Human Interleukin-2 for Injection and Azithromycin for Injection have become national famous brands. Meantime, by help of abundant funds, the company has continuously strengthened new product development and established long-term cooperative relationships with Southeast University, Jiangnan University and other higher education institutions. At present, long-acting recombinant human interleukin-2 and lansoprazole for injection are being researched and developed.
Taking as our own responsibility work for human health and keeping conscientious attitude towards science, as well as practical working style, the company continuously researches, develops and produces medicine with stable quality and exact effect. Meantime, with the operation principle of “seeking mutual successes with customers”, the company is ready to establish cooperative relationships with international customers to jointly work for human health!
|
